Glenmark Pharmaceuticals (NSE:GLENMARK) Institutional Ownership: 25.47% (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLENMARK Glenmark Pharmaceuticals Ltd NSE:GLENMARK
85 GF Score
Price ₹2,460.00
GF Value ₹2,188.90
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Glenmark Pharmaceuticals Institutional Ownership?

Glenmark Pharmaceuticals NSE:GLENMARK -0.42% 85 Institutional Ownership is 25.47% as of Sep. 03, 2026. GuruFocus rates NSE:GLENMARK with a GF Score™ of 85/100 and a GF Value™ of ₹2,188.90 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Glenmark Pharmaceuticals's institutional ownership is 25.47%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Glenmark Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Glenmark Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 0.00%.

Glenmark Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Glenmark Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glenmark Pharmaceuticals Institutional Ownership Chart

Glenmark Pharmaceuticals Historical Data

The historical data trend for Glenmark Pharmaceuticals can be seen below:

2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31 2026-08-31
Institutional Ownership 28.43 26.50 26.13 26.09 25.40 25.24 25.38 25.72 25.40 25.47
NSE:GLENMARK
85GF Score
Glenmark Pharmaceuticals Ltd NSE:GLENMARK
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glenmark Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 25.47% mean?
Glenmark Pharmaceuticals (NSE:GLENMARK) has a Institutional Ownership of 25.47% as of Sep. 03, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Glenmark Pharmaceuticals and its competitors.
Is Glenmark Pharmaceuticals' Institutional Ownership too high?
Glenmark Pharmaceuticals' current Institutional Ownership is 25.47%. Overall, Glenmark Pharmaceuticals has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' Institutional Ownership compare to ZTS?
Glenmark Pharmaceuticals' Institutional Ownership of 25.47% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Glenmark Pharmaceuticals and its competitors. Glenmark Pharmaceuticals's current Institutional Ownership is 25.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,188.90, compared to a current price of ₹2,460.00 — trading 12.4% above its estimated fair value. The current Institutional Ownership is 25.47%. Glenmark Pharmaceuticals' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current Institutional Ownership is 25.47% as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?

Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued. The current stock price of ₹2,460.00 is trading 12.4% above its estimated GF Value™ of ₹2,188.90. GuruFocus considers Glenmark Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for NSE:GLENMARK:

  • Institutional Ownership: 25.47%
  • GF Value™: ₹2,188.90 vs. price of ₹2,460.00 (12.4% above fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glenmark Pharmaceuticals Business Description

Other Exchanges 532296:India
Address B. D. Sawant Marg, Glenmark House, Chakala, Off Western Express Highway, Andheri (East), Mumbai, MH, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
85GF Score

Get the complete analysis for NSE:GLENMARK

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,460.00
Price
₹2,188.90
GF Value